Short-Term Outcomes of Apixaban Versus Warfarin in Patients With Atrial Fibrillation

Gregory Y H Lip^{1

2}, Ahsan A Khan¹, Brian Olshansky³

Affiliations

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Merseyside, United Kingdom (G.Y.H.L., A.A.K.).
² Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.H.Y.L.).
³ Department of Internal Medicine, Carver College of Medicine, University of Iowa Health Care, Iowa City (B.O.).

Editorial

Gregory Y H Lip et al. Circulation. 2019.

. 2019 May 14;139(20):2301-2303.

doi: 10.1161/CIRCULATIONAHA.119.040021.

Gregory Y H Lip^{1

2}, Ahsan A Khan¹, Brian Olshansky³

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Merseyside, United Kingdom (G.Y.H.L., A.A.K.).
² Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.H.Y.L.).
³ Department of Internal Medicine, Carver College of Medicine, University of Iowa Health Care, Iowa City (B.O.).

No abstract available

Keywords: Editorials; apixaban; arfarin; atrial fibrilliation; thromboembolism.

Comment on

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD. Hohnloser SH, et al. Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955. Circulation. 2019. PMID: 30773022